Patients receiving IFN-α therapy for hepatitis C also have elevated levels of endothelin-1 (ET-1), a key mediator involved in the pathogenesis of PAH, and ET-1 can be induced by interferon in vascular smooth muscle [95]. The gene discussed is EDN1; the disease is hepatitis C virus infection.